CymaBay Therapeutics Inc logo

CymaBay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. It is developing seladelpar, which is in Phase IIb clinical trials for the treatment of primary biliary cholangitis (PBC) and in Phase II trials for the treatment of bile acid diarrhea; MBX-2982 that is in preclinical development stage; and MBX-8025 to treat homozygous familial hypercholesterolemia. The company was founded in 1989 and is headquartered in Newark, California.

Latest events on Quartr

Previous Events for CymaBay Therapeutics Inc




United States of America

About the company

Investor Relations page

Dig deeper into the fundamentals using Quartr - Investor relations

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
Android play link
App store link
Quartr app screenshot